Document is current
Any future updates will be listed below
-
Authors
Mitchell, Joshua D. https://orcid.org/0000-0001-7371-5742
Pfeiffer, Michael https://orcid.org/0000-0002-6472-7896
Boehmer, John
Gorcsan, John
Eguchi, Shunsuke https://orcid.org/0009-0007-6436-8110
Orihara, Yoshiyuki https://orcid.org/0000-0002-7438-8250
Dronamraju, Nalina
Dhani, Sonja
Faderl, Stefan
Lin, Tara L. https://orcid.org/0000-0002-0242-6449
Uy, Geoffrey L.
Lancet, Jeffrey E.
Cortes, Jorge E.
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 14 November 2025
First Online: 25 November 2025
Declarations
:
: Ethics approval and consent were obtained for the phase III trial. This is a post hoc analysis.
: Not applicable.
: JDM has received consulting fees from Alnylam, Altathera, AstraZeneca, Bridgebio, Pfizer, and Race Oncology; and research funding from Myocardial Solutions and Abbott Laboratories. MP has received consulting/advisory fees from Ancora Heart, speakers’ bureau fees from Abbott Laboratories, and institutional research funding from BioVentrix. JG has received institutional research funding from Jazz Pharmaceuticals. ND was an employee of and held stock ownership/options in Jazz Pharmaceuticals during manuscript development. SD is an employee of and holds stock ownership/options in Jazz Pharmaceuticals. SF is an employee of and holds stock ownership/options in Jazz Pharmaceuticals; and has received honoraria and travel or accommodation expenses from Jazz Pharmaceuticals. TLL has received institutional research funding from Aptevo Therapeutics, Astellas Pharma, BioPath Holdings Inc, Celyad, CicloMed, Cleave Therapeutics, and Jazz Pharmaceuticals, and has served as a consultant for Servier and Jazz Pharmaceuticals. GLU has received consulting/advisory fees from Jazz Pharmaceuticals and Novartis. JEL has received consulting/advisory fees from Bristol Myers Squibb, Prelude Therapeutics, and Treadwell Therapeutics; and a member of their immediate family has stock ownership/options in Arvinas. JEC has received consulting/advisory fees from BioPath Holdings Inc, Bristol Myers Squibb, Centessa Pharmaceuticals, Gilead Sciences, Menarini, Novartis, Pfizer, and Takeda; and institutional research funding from AbbVie/Genentech, Actuate Therapeutics, Astellas Pharma, BioPath Holdings Inc, Bristol Myers Squibb, Jazz Pharmaceuticals, Novartis, Pfizer, Sellas Life Sciences, Sun Pharma, and Takeda. The remaining authors have no relationships to disclose.
